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Abstract
Background: Optimal timing of ART initiation for individuals presenting with AIDS-related OIs has not been defined.
Methods and Findings: A5164 was a randomized strategy trial of ‘‘early ART’’ - given within 14 days of starting acute OI
treatment versus ‘‘deferred ART’’ - given after acute OI treatment is completed. Randomization was stratified by presenting
OI and entry CD4 count. The primary week 48 endpoint was 3-level ordered categorical variable: 1. Death/AIDS progression;
2. No progression with incomplete viral suppression (ie HIV viral load (VL) $50 copies/ml); 3. No progression with optimal
viral suppression (ie HIV VL ,50 copies/ml). Secondary endpoints included: AIDS progression/death; plasma HIV RNA and
CD4 responses and safety parameters including IRIS. 282 subjects were evaluable; 141 per arm. Entry OIs included
Pneumocytis jirovecii pneumonia 63%, cryptococcal meningitis 12%, and bacterial infections 12%. The early and deferred
arms started ART a median of 12 and 45 days after start of OI treatment, respectively. The difference in the primary
endpoint did not reach statistical significance: AIDS progression/death was seen in 20 (14%) vs. 34 (24%); whereas no
progression but with incomplete viral suppression was seen in 54 (38%) vs. 44 (31%); and no progression with optimal viral
suppression in 67 (48%) vs 63 (45%) in the early vs. deferred arm, respectively (p=0.22). However, the early ART arm had
fewer AIDS progression/deaths (OR=0.51; 95% CI=0.27–0.94) and a longer time to AIDS progression/death (stratified
HR=0.53; 95% CI=0.30–0.92). The early ART had shorter time to achieving a CD4 count above 50 cells/mL (p,0.001) and no
increase in adverse events.
Conclusions: Early ART resulted in less AIDS progression/death with no increase in adverse events or loss of virologic
response compared to deferred ART. These results support the early initiation of ART in patients presenting with acute
AIDS-related OIs, absent major contraindications.
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Introduction
Over the past decade there has been remarkable progress in the
treatment of HIV-1 infection. As a result of potent combination
antiretroviral therapy (ART), HIV-infected individuals are living
longer and healthier lives. [1–3] Even patients who initiate
treatment relatively late in the disease course have been shown to
benefit from ART treatment. [4–6]. Despite these advances,
mortality rates remain unacceptably high in populations with poor
access to health care services such as communities of color, young
adults, and poor rural and inner-city dwellers [7–12] who
frequently first enter HIV care with acute AIDS-related
opportunistic infections (OIs). In addition, many thousands of
HIV-infected individuals are accessing ART in Resource-poor
settings, often with advanced AIDS.
As we enter the second decade of effective ART, an important
clinical question has remained unanswered: when should ART be
started in the management of a patient with an acute OI?
Concurrent treatment of the OI and HIV might result in higher
morbidity and/or mortality by increasing toxicity of treatment,
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regimen, and increasing the frequency of immune reconstitution
and inflammatory syndrome (IRIS) reactions. Alternatively,
concurrent treatment might decrease patient morbidity/mortality
by restoring pathogen-specific immune responses and speeding
immune reconstitution.
In this randomized trial, we address the optimal timing of ART
in the setting of an acute OI by evaluating two clinical approaches
or strategies; ‘‘early ART’’ intended to be initiated during OI
treatment, and ‘‘deferred ART’’ intended to be initiated after
treatment of the acute OI is completed.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Trial Design
AIDS Clinical Trials Group (ACTG) A5164 was an open-label,
randomized, phase IV, strategy study of early-versus-deferred
ART in subjects who presented with acute AIDS-related OIs or
serious bacterial infections (BIs) for which effective antimicrobial
therapies were available. The OIs were a subset of the 1999
CDC’s AIDS-defining conditions or treatable AIDS-related OIs
[13]. (See Appendix S1.)
After eligibility checklist (including safety laboratories) was
completed, randomized treatment assignment was generated by
central computer using permuted blocks within strata. Neither the
size of the blocks nor treatment assignments to other sites were
public, preventing individual investigators from deducing the
assignment pattern. Randomization was stratified by CD4 cell
count (, or $50 cells/mm
3) and by first treated OI/BI at study
entry (PCP, vs. BIs, vs. all other OIs).
Subjects had to be randomized within 14 days of starting
therapy for the OI/BI that determined study eligibility. Subjects in
the early arm (also referred to as ‘‘immediate arm’’ in study
protocol) were expected to start ART within 48 hours of study
enrollment. Subjects in the deferred arm were encouraged to start
ART between week 6 (day 42) and week 12 (day 84) of the study;
to receive study-provided ART, they were required to start
treatment between week 4 (day 28) and week 32 (day 224).
Subjects in the deferred arm who started ART outside this window
were not offered study-provided ART but were included in
analyses. All subjects in both arms were followed for 48 weeks,
regardless of whether they started or continued ART and were
included in the analyses.
The primary endpoint of the study was a 3-level, ordered,
categorical variable: alive without AIDS progression and with
HIV viral load ,50 copies/mL (best outcome) at week 48; alive
without AIDS progression and with detectable HIV viral load (i.e.
VL .=50 copies/ml) at week 48 (intermediate outcome); and
AIDS progression or death (worst outcome) at any time. New
AIDS-defining events diagnosed in the first 30 days of the study
were not considered to be endpoints because it was highly likely
they existed at entry but were not diagnosed until a more thorough
work-up after the acute event was under control. Sensitivity
analyses were conducted with a 15 day window to confirm results.
Endpoints were also evaluated without the 30-day window.
Several of the planned secondary outcomes reported here include
clinical outcomes: death/AIDS progression independent of
virologic response; virologic response independent of clinical
endpoints; changes in CD4 counts from baseline over 48 weeks;
safety and tolerability of ART; hospitalizations; self-reported ART
adherence; and incidence of IRIS. Other secondary endpoints on
incidence of drug resistance, quality of life and functional status as
well as a formal cost-effectiveness analysis will be the focus of
future manuscripts.
Subjects
Eligible subjects were HIV-infected men or women .13 years
old, presenting with an AIDS-defining OI or serious BI for which
effective antimicrobial therapy was available and prescribed. To
reflect clinical practice, the trial allowed presumptive and
confirmed diagnoses as long as appropriate treatment for the
OI/BI had been initiated (cryptococcal disease was required to be
confirmed). Subjects with BIs must have had a CD4 count
confirmed of ,200 cells/mm
3. Subjects with or on treatment for
tuberculosis (TB) were excluded. Subjects in whom TB was
diagnosed after randomization remained in the study. Subjects
were ineligible if they had received ART within 8 weeks prior to
study entry, more than 31 days of any ART within 6 months prior
to study entry, or more than one ART regimen on which they
experienced treatment failure. Recruitment was conducted at 39
AIDS Clinical Trials Units in the United States (including Puerto
Rico), and Johannesburg, South Africa (which was limited to
enrolling 20 subjects by the study sponsor). (see Appendix S2 for
complete investigator listing)
Ethics statement. All participating sites had local
Institutional Review Board approval. All subjects provided
written informed consent.
Treatment Regimens
The study provided lopinavir/ritonavir [LPV/r], emtricitabine
[FTC], tenofovir disoproxil fumarate [TDF], and stavudine [d4T].
However, any antiretroviral agent approved by the FDA for the
initial treatment of HIV was allowed. The study recommended
that ART include a ritonavir-boosted protease inhibitor (PI/r) or
non-nucleoside reverse transcriptase inhibitor (NNRTI) in combi-
nation with 2 nucleoside reverse transcriptase inhibitors (nRTIs)
that included lamivudine [3TC] or emtricitabine [FTC], but the
choice of ART was left to the judgment of the clinician to better
reflect common clinical practice.
Study Schedule
Subjects were seen at weeks 4, 8, 12, 16, and every 8 weeks
thereafter through week 48 for clinical assessments and routine
laboratory monitoring. Subjects in the deferred arm shifted to
follow-up at weeks 4, 8, 12,and 16 after initiationof ART and every
8 weeks thereafter until week 48. Adverse events were graded from
Grade 2 (moderate) to Grade 4 (worst) according to the Division of
AIDS Table for Grading the Severity of Adult and Pediatric
Adverse Events: December 2004. Grade 2 events were only
reported if they lead to a modification or discontinuation of ART.
They are presented here for completeness, as ART management is
an important consideration of this study. Clinical assessments and
laboratories were also measured at time of suspected IRIS and
premature ART or study discontinuation. Adherence documenting
missed doses over the prior four days and within 3 months was
assessed by self-report at weeks 8, 16, 32 and 48. The National
Institute of Allergy and Infectious Diseases’ Data and Safety
Monitoring Board (DSMB) reviewed the study annually.
IRIS Case Definition
The definition of IRIS was: evidence of an increase in CD4+
cell counts and/or decrease in plasma viral load in response to
ART; and symptoms consistent with an infectious/inflammatory
Early ART in AIDS-Related OIs
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not be explained by a newly acquired infection, the expected
clinical course of another agent, or side effects of ART itself. All
cases of IRIS required review by a study chair, blinded to
treatment group and site. One case that could not be blinded was
reviewed by a third reviewer who was not part of the study team.
Statistical Considerations
Analyses of the primary ordered endpoint and related secondary
endpoints were conducted with exact Wilcoxon tests stratified by
entry CD4 count and OI/BI and logistic regression adjusted for
entry CD4 count and OI/BI. Analyses of related censored data
were conducted with stratified Cox regression. Unstratified tests
were conducted as appropriate, including: dichotomous covariates
with Fisher’s exact tests; ordered and continuous data with
Wilcoxon and Kruskall-Wallis tests; logistic regression and
censored data with unstratified logrank tests. Baseline in all
analyses was defined as the date of randomization. Loss to follow-
up and, where not the endpoint, deaths were censored in failure-
time analyses. Cumulative incidence models with death as a
competing risk were evaluated. Curves depicting censored data are
based on the method of Kaplan and Meier and do not reflect
stratification.
The target sample size was 141 per arm to provide at least 80%
power for a range of plausible alternatives for the distribution of
the primary endpoint, based on improving the proportion in the
best outcome by approximately 20% (e.g. 40% to 60%) and a
reduction by 1/3 in the worst outcome (e.g., 15% to 10%). The
expected lost to follow up rate was 10%–15%. The DSMB
reviewed one formal interim analysis and thus the primary and
related secondary endpoints should be evaluated with respect to a
two-sided 0.0448 p-value.
Results
A5164 enrolled 283 subjects between May 2003 and August
2006. The last subject completed the study in August of 2007 and
data entry was completed by January 2008. One subject withdrew
consent on the day of randomization and is not included in the
analysis. (Figure 1) Baseline demographic and clinical character-
istics for the 282 evaluable subjects were well balanced across arms
(Table 1). Subjects were primarily men (85%), with a median age
of 38 years. The ethnicity of subjects was diverse: 37% Black, 36%
Hispanic, and 23% White. Most subjects reported never used
injection drugs. The baseline median CD4 count was 29 cells/
mm
3, 70% of subjects entered the study with a CD4 count of ,50
cells/ml. The baseline plasma log10 HIV VL was 5.07 copies/mL.
Over 90% of subjects were ART naı ¨ve.
The most common entry OIs included PCP (63%), cryptococcal
meningitis (12%), and BIs (12%). (Table 1) One-third of subjects
Figure 1. Study Subject Enrollment and Discontinuation.
doi:10.1371/journal.pone.0005575.g001
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additional ones within the first 30 days of study entry.
ART Management
All subjects in the early arm and 129 (91%) of subjects in the
deferred arm initiated ART. Figure 2 shows that the early arm
initiated ART a median of 12 days [IQR, 9–13 days] after OI
treatment initiation while the deferred arm started ART a median
of 45 days [IQR, 41–55 days] after initiation of OI treatment. The
median time to start of ART from randomization was day 0 [IQR
0–1 days] in the early arm vs. day 35 [IQR, 29–44 days] in the
deferred arm. There was no overlap in the time to initiation of
ART between the study arms – even though the protocol allowed
for clinician discretion in ART start times outside of the targeted
windows.
There were no significant differences between the arms in initial
ART regimens used. A boosted PI with two nRTIs was used in
89% of subjects in the immediate arm and 85% of subjects in the
deferred arm while NNRTI-based regimens with two nRTIs were
used in 11% and 16%, respectively. Only one subject was
prescribed an all nRTI regimen (trizivir+TDF). Lopinavir/r was
the boosted PI used in 82% of regimens in the immediate arm and
71% of regimens in the deferred arm. There were somewhat more
ART changes in the immediate arm (p=0.20). The reasons for
treatment changes were not different across the two arms (data not
shown). At week 48, for subjects on ART –over 90% of subjects
who completed questionnaires in both arms reported taking ART
within the last four days ‘most’ or ‘all’ of the time, and 59% of
subjects in both arms reported never having missed a dose in the
prior three months.
Study Outcomes
Eighty-seven percent of subjects, 123 in each arm, were
evaluable for the primary endpoint. (Table 2) There was no
statistically significant difference in the ordered 3 category primary
endpoint at 48 weeks: AIDS progression/death in 20 (14%) vs. 34
(24%); 54 (38%) vs. 44 (31%) had no progression or death but viral
load $50 copies/ml; and 67 (48%) vs. 63 (45%) had no
progression or death and viral load of ,50 copies/ml at week
48 in the early versus the deferred arms, respectively (p=0.22). Per
the study design, the 18 subjects in each arm with no endpoint
information were included in the intermediate outcome group.
However, excluding these subjects or assigning them to the other
categories of outcome did not alter the result (data not shown).
Moreover, sensitivity analyses including AIDS defining endpoints
that occurred in the first 30 days after study entry did not alter the
study results (data not shown).
Importantly, a difference in clinical outcomes between the study
arms was observed in a secondary analysis that evaluated the rates
of AIDS progression or death. Twenty subjects (14.2%) in the
early arm died or had progression of disease compared to 34
subjects (24.1%) in the deferred arm (stratified p=0.035;
OR=0.51; 95%CI: 0.27–0.94). Furthermore, time to AIDS
progression/death also favored the early ART arm (p=0.02;
HR=0.53; 95%CI: 0.30–0.92). (Figure 3) AIDS progression
events were, for the most part, significantly morbid AIDS-related
conditions, and deaths were primarily AIDS-related opportunistic
infections or malignancies. (Table 3) The differences between the
study arms were maintained when AIDS-defining events within
the first 30 days of randomization were included as endpoints (data
not shown).
Table 1. Baseline Demographic and Clinical Characteristics by Strategy Arm*.
Characteristic Total Early Deferred
Number 282 141 141
Men (%) 241 (85) 120 (85) 121 (86)
Women (%) 41 (15) 21 (15) 20 (14)
Black (%) 103 (37) 51 (36) 52 (37)
Hispanic (%) 101 (36) 52 (37) 49 (35)
White (%) 64 (23) 29 (21) 35 (25)
Asian (%) 13 (5) 8 (6) 5 (4)
Age [median yrs] (IQR) 38 (32–44) 39 (33–44) 38 (32–44)
IDU never (%) 246 (87) 124 (88) 122 (87)
CD4 (cells/mm
3) Median (IQR) 29 (10–55) 31 (12–54) 28 (10–56)
HIV RNA (log10) Median (IQR) 5.07 (4.71–5.63) 5.07 (4.74–5.59) 5.08 (4.64–5.64)
No Prior ART 259 (92) 131 (93) 128 (91)
PCP 177 (63) 88 (62) 89 (63)
BI 34 (12) 17 (12) 17 (12)
Other OI 71 (25) 36 (26) 35 (25)
Cryptococcus 35 (12) 13 (9) 22 (16)
Toxoplasmosis 13 (5) 9 (6) 4 (3)
Histoplasmosis 10 (4) 7 (5) 3 (2)
CMV 6 (2) 4 (3) 2 (1)
MAC 6 (2) 3 (2) 3 (2)
Multiple OI/BI (w/in 30 days) 92 (33%) 45 (32%) 47 (33%)
*No statistically significant differences were noted for the various comparisons.
doi:10.1371/journal.pone.0005575.t001
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diagnoses in a post-hoc analysis. (Figure 4). Entry diagnoses were
confirmed independently by two study team members after the
study was closed and all required clinical data was completed and
submitted by the sites. Since subjects could have more than 1
confirmed OI/BI, some subjects were included in more than one
category. The figure reveals that for all categories of confirmed
diagnoses early ART appears to be associated with less clinical
progression (i.e. OR ,1.0) compared to deferred ART. However,
many of the categories lack appropriate power to be reach a
standard level of statistical significance but we see statistically
significant results for overall, fungal infections (includes crypto-
coccal infections and histoplasmosis) and those entering with CD4
count of less than 50 cells/mm
3.
The time to a CD4+ count .50 cells/mm
3 was 4.0 weeks versus
8.6 weeks and time to CD4+ count greater than 100 cells/mm
3
was 4.3 weeks vs. 12.0 weeks in the early-versus-deferred arm,
respectively (p,0.001 for both comparisons). (Figure 5) However,
both arms eventually reached similar CD4+ counts by week 24,
and median CD4+ count at week 48 was 220 cells/mm
3 in the
immediate arm compared to 233 cells/mm
3 in the deferred arm.
Furthermore, virologic control (independent of AIDS progression
events) was nearly identical in the two arms; 71 immediate ART
and 72 deferred ART subjects achieved a viral load of ,50
copies/mL at week 48 based on a standard ITT analysis (lost or
death by week 48=fail). (Table 2)
Adverse Events
The number of subjects reporting moderate or worse (Grades 2,
3 and 4) new signs and symptoms were 14, 40, and 7 subjects in
the immediate arm and 34, 29, and 6 subjects in the deferred arm
(p=0.87; Grade 2 reported only for ART regimen change).
Table 4 shows the types of signs and symptoms did not differ
across the arms. No significant differences were observed in the
rates of laboratory abnormalities across the study arms with the
exception of more Grade 3 absolute neutrophil count depression
in the deferred arm (p=0.05). (Table 5) Hospitalizations and
number of hospital days were also not different in the two arms.
(Table 2)
IRIS was reported in 23 cases and confirmed in 20: 8 subjects in
the immediate arm and 12 in the deferred arm. There was no
evidence of an association of IRIS with the entry OI/BI: 13 (65%)
IRIS cases were in subjects with PCP who comprised 63% of the
study population. IRIS developed a median of 33 days [IQR: 26,
72 days] after initiation of ART. There was no significant
difference in the frequency of IRIS between subjects who received
corticosteroids during the treatment of their OI and those who did
not receive corticosteroids; 9/150 (6%) versus 11/112 (9.8%),
respectively (p=0.35).
Discussion
This strategy trial did not demonstrate a significant result in the
primary outcome: an ordered categorical endpoint at one year
that combines clinical and virologic outcomes. This combined
outcome was chosen because we did not believe we would see a
significant difference in the incidence of AIDS progression and/or
death alone given our sample size and best estimates of progression
rates in the HAART era. However, because the composite
endpoint incorporated an assessment of viral load at 1 year, which
was essentially identical in both arms, the differences between the
Figure 2. Time to ART initiation from the start of OI/BI treatment. Early arm median 12 days [IQR 9–13 days]; Deferred arm median 45 days
[IQR 41–55 days].
doi:10.1371/journal.pone.0005575.g002
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Outcome Total Early Deferred p-value
No Endpoint Information 36 (12.8%) 18 (12.8%) 18 (12.8%)
Primary Endpoint
AIDS Progression/Death 54 (19.1%) 20 (14.2%) 34 (24.1%)
Plasma Viral Load .50 copies; no progression* 98 (34.8%) 54 (38.3%) 44 (31.2%)
Plasma Viral Load ,50 copies; no progression 130 (46.1%) 67 (47.5%) 63 (44.7%)
0.215
a
Secondary Endpoints
AIDS Progression/Death 54 (19.1%) 20 (14.2%) 34 (24.1%) 0.035
b
HIV VL % ,50 copies at 48 wks (ITT analysis) 143 (51%) 71 (50%) 72 (51%) 0.48
c
CD4 count at 24 weeks (median change from baseline) (IQR ) +115 (+71–+180) +118 (+75–+186) +104 (+66–+171) 0.22
c
CD4 count at 48 weeks [median change from baseline] (IQR) +187 (+106–+269) +187 (+95–+268) +187 (+124–+271) 0.50
c
Safety Outcomes
Had at least one ART Switch or interruptions, 104 (39%) 59 (42%) 45 (35%) 0.26
d
IRIS Confirmed 20 (7.1%) 8 (5.7%) 12 (8.5%) 0.49
d
Laboratory Adverse Events Grades 2–4 192 (68%) 90 (64%) 102 (72%) 0.16
d
Clinical Adverse Events Grades 2–4 130 (46%) 61 (43%) 69 (50%) 0.40
d
Subjects with Hospitalization 106 (38%) 55 (39%) 51 (36%) 0.71
d
Median Hospital Days (among hospitalizations) 5 (2–10) 5 (2–10) 6 (2–10) 0.79
c
*Includes subjects with missing outcomes.
aStratified Wilcoxon Rank Sum test.
bStratified exact test.
cWilcoxon Rank Sum.
dFisher’s Exact Test.
doi:10.1371/journal.pone.0005575.t002
Figure 3. Time to AIDS progression or death. HR=0.53 Early versus Deferred ART [95%CI 0.30–0.92 p=0.023].
doi:10.1371/journal.pone.0005575.g003
Early ART in AIDS-Related OIs
PLoS ONE | www.plosone.org 6 May 2009 | Volume 4 | Issue 5 | e5575groups were not significant on our primary combined outcome. In
effect, the equivalent virologic outcomes at 1 year ‘‘diluted’’ the
larger than anticipated positive impact of early ART on clinical
outcomes.
There was a significant difference favoring the early treatment
group in the secondary outcome of AIDS progression/death. The
impact is seen primarily on morbidity and mortality events in the
first 6 months (see Figure 3), suggesting that early improvement in
immune responsiveness is critical to prevent clinical progression.
Subjects in the early ART arm spent less time with CD4 counts
,50 or ,100 and therefore the ‘‘window of vulnerability’’ to
additional AIDS-related complications was shortened by early use
of ART. The idea that ART seems to have an early effect on the
clinical course following an OI is supported by our finding that
early ART was beneficial even though the difference in the time to
initiation of ART following the OI was only about 1 month. The
difference in outcomes could not be explained by differences in
ART regimens used, adherence, adverse events or number of
hospitalizations (which were similar in the two arms).
Because AIDS progression/death was not the primary outcome
of our study, we recognize that our results should be interpreted
cautiously. On the other hand, AIDS progression/death is an
important (it could be argued the most important) outcome for
ART trials, and our results are consistent with the biologic effects
of ART treatment. These findings extend the results of landmark
clinical trials that ushered in the first decade of effective ART in
patients with advanced immunodeficiency but without active OIs.
[4–6] In retrospect, one would not expect that a 1 month
difference in ART treatment would significantly impact viral load
response at 1 year if the patient survives the period immediately
following OI without further complications.
Surprisingly, IRIS was uncommon in this study (7%) although
subjectshadveryadvanced immunodeficiency,werereceivingART
early in their OI treatment course, and had good increases in CD4
counts - all conditions that have been associated with IRIS. From
published case seriesandclinicalcohorts, the incidence ofIRIS after
ART initiation has ranged from 15% to 45% [14–19]. It is not clear
why the rate of IRIS was low in this trial. However, we do not
believe it is because cases were being missed given the special efforts
that the study team made to find cases including a team review of all
subjects who received corticosteroids that identified no unreported
IRIS cases. The use of predefined criteria and real-time review in
this prospective study may have reduced case finding bias. In
support of this is another recently published prospective study
reporting a similar rate of IRIS in a South African population. [20]
Although IRIS has been reported for many AIDS-related OIs,
the risk is likely to vary by OI and corticosteroid use. We conclude
that IRIS is less frequently a complication of ART in the setting of
the OIs included in this study– most particularly PCP - than has
been the impression from retrospective studies to date. We don’t
believe that corticosteroid use influenced the overall incidence of
IRIS but may have deferred its onset. However, other infections
like TB may have higher rates of IRIS. TB at entry was excluded
in this study but is being studied in a second ACTG study. At least
for the spectrum of OIs included in this study, fear of IRIS should
not be a reason to defer ART.
Initiating ART early required slightly more ART changes but
this did not appear to have a deleterious impact on outcomes. On
the positive side, starting ART early may better assure that
patients have an opportunity to benefit from this life-saving
treatment. In this study, all subjects in the early arm initiated
ART, but 9% of the subjects in the deferred arm never did. This
Table 3. Death and AIDS Progression Events (after day 30) by Strategy Arm.
AIDS Diagnosis Early ART Deferred ART
Fatal Non-Fatal Fatal Non-Fatal
Esophageal Candidiasis 0 2 0 3
Cryptococcal meninigitis 0 1 2 1
Disseminated Histoplasmosis 1 0 0 2
Invasive Aspergillosis 0 0 1 0
CMV 0 1(1) 0 3(2)
K S 01 01
Lymphoma 4 0 0 0
Disseminated MAC (or other atypical mycobacterial infection) 0 3 3 3(1)
T B 12 03
P C P 10 31 ( 1 )
Pneumonia, recurrent 0 1 0 2(1)
Toxoplasmosis or Cryptosporidiosis 0 0 0 2
Wasting Syndrome 0 0 0 1
Sepsis 0 0 3 0
O t h e r * 11 11
No Information 2 0 1 0
TOTAL Events 10 12(1) 14 23(5)
TOTAL Subjects 10 10 14 20
*Fatal events: Cocaine Intoxication @ week 54 in Immediate arm, Cirrhosis death week 21 in deferred; Non-fatal events 1 case of HSV .1 mo in each study arm.
Events in parentheses are additional non-fatal events which occurred in people who died.
doi:10.1371/journal.pone.0005575.t003
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deferred ART. Total, fungal and CD4,50 categories represent significance at p,0.05. (Fungal Infections include cryptococcal infections and
histoplasmosis).
doi:10.1371/journal.pone.0005575.g004
Figure 5. Time to CD4.50 cells/mm3; Early ART median time 4.0 weeks (IQR 0–5.0 weeks) versus deferred ART median time 8.1
weeks (IQR 0–12.7 weeks). Right side graph: Time to CD4.100 cells/mm3; Early ART median time 4.3 weeks (IQR 4.0–23.6 weeks) versus Deferred
ART median time 12.1 weeks (IQR 8.6–28.1 weeks) (p,0.001 for both comparisons).
doi:10.1371/journal.pone.0005575.g005
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PLoS ONE | www.plosone.org 8 May 2009 | Volume 4 | Issue 5 | e5575can be seen as another potential benefit to the strategy of initiating
ART early. If ART is deferred there may be a ‘‘lost opportunity’’
to intervene (either because patients become progressively more ill
or died or are lost to follow up medical care) and this effect may be
even larger in the context of clinical practice as opposed to a
clinical trial wherein additional resources are available and
additional efforts are made to follow and treat subjects. Individuals
who present to care with late stage AIDS without benefit of prior
ART are often seen as being at high risk for non-adherence and
poor medical follow up. However, we believe that given these
study results practitioners should at least offer ART early in the
treatment course of the OI to these patients.
An important strength of this strategy study is that it was
designed to mirror most aspects of clinical practice. Physicians
Table 4. ACTG A5164 Clinical Adverse Events (New Signs and Symptoms of Grade 2 or Higher over 48 weeks).
Treatment Group
Early (N=141) Deferred (N=141) All (N=282)
Toxicity Grade Toxicity Grade Toxicity Grade
Toxicities 2 3 4 5
Number
subjects 2 3 4 5
Number
subjects 2 3 4 5
Number
subjects
Any General Body 10 23 2 0 35 17 13 1 0 31 27 36 3 0 66
Any Respiratory 7 8201 7 76201 5 1 4 1 4 403 2
Any Circulatory/Cardiac 3 1004 23005 54009
A n y H e m a t o l o g y 11002 40105 51107
A n y H e m a t o l o g y , S i g n s a n d S y m p t o m s 11002 40105 51107
Any Liver/Hepatic 1 1002 00000 11002
Any Gastro-Intestinal 9 9202 0 1 5 9002 4 2 4 1 8 204 4
Any Renal 0 1001 00000 01001
Any Reproductive 3 0003 21104 51107
Any Skin 7 8101 6 1 5 5002 0 2 2 1 3 103 6
Any Neurological 11 13 1 0 25 18 13 4 0 35 29 26 5 0 60
Any Special Senses 2 0002 02002 22004
A n y O t h e r 11103 21003 32106
ANY SIGN/SYMPTOM 14 40 7 0 61 34 29 6 0 69 48 69 13 0 130
Table reflects the number of subjects reporting each symptom/toxicity.
Grade 0=Normal, 1=Mild, 2=Moderate, 3=Severe, 4=Life-Threatening, 5=Death.
The worst grade for each Symptom category is reported.
doi:10.1371/journal.pone.0005575.t004
Table 5. A5164 Laboratory Adverse Events (New Laboratory Abnormalities of Grade 2 or Higher over 48 weeks).
Treatment Group
Early (N=141) Deferred (N=141) All (N=282)
Toxicity Grade Toxicity Grade Toxicity Grade
Toxicities 2 3 4 5
Number
subjects 2 3 4 5
Number
subjects 2 3 4 5
Number
subjects
Any Chemistry 20 10 8 0 38 23 12 5 0 40 43 22 13 0 78
Any Chemistry, General 20 10 8 0 38 23 12 5 0 40 43 22 13 0 78
A n y H e m a t o l o g y 1 3 9702 9 1 1 2 2 1 0 04 3 2 4 3 1 1 7 07 2
Any Hematology, Coagulation 4 1308 43108 84401 6
A n y H e m a t o l o g y , R B C 42107 44301 1 86401 8
Any Hematology, WBC/Differential 5 8601 9 71 8 703 2 1 2 2 6 1 3 05 1
A n y M e t a b o l i c 1 3 8302 4 1 9 5102 5 3 2 1 3 404 9
Any Liver/Hepatic 8 14 5 0 27 23 10 6 0 39 31 24 11 0 66
Any Renal 3 1206 44109 75301 5
Any Pancreatic 6 17 0 0 23 11 13 5 0 29 17 30 5 0 52
ANY TOXICITY 31 39 20 0 90 36 45 21 0 102 67 84 41 0 192
doi:10.1371/journal.pone.0005575.t005
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our study to only the treatment of definitive diagnoses, it may not
have generalized to the care of patients treated presumptively.
Also, we allowed for a range of starting points in ART treatment
within both arms because that too reflects the realities of clinical
practice. Although AIDS progression/death was not the primary
outcome of our study, it is an important standard by which to
judge the outcome of ART trials. Our findings most directly reflect
the spectrum of opportunistic and serious bacterial infections seen
in the resource-rich countries where the majority of the patients
were enrolled. These results also reflect a primarily ART naı ¨ve
population, in patients with prior ART therapy and drug
resistance the impact of early ART may be more attenuated.
Additional randomized controlled studies are required for TB
(ongoing) and cryptococcal infections given our lack of power to
provide a definitive result in this study.
Our study can be viewed as demonstrating the efficacy of early
ART since there was selection by treating clinicians for patients that
were likely to be ‘‘good’’ clinical trial candidates. We have no way to
know how much ‘‘pre-screening’’ of patients occurred but treating
clinicians were instructed to use ‘‘best clinical judgment’’ in selecting
patients for the study. Although there was likely some ‘‘pre-selection’’
of patients, this is no different than any other randomized clinical trial
and since there were 40 participating sites across a wide spectrum of
clinical settings in the US (and South Africa) we feel the study results
are fairly generalizable. Studies of the effectiveness of this strategy in
other populations who might be less-idealclinical trialcandidates -like
injection drug users - may be required to further generalize our
findings but even more challenging to conduct.
We would be cautious to generalize these results to resource-
limited countries, even though patients in those countries are
accessing ART with advanced AIDS and with some of these same
OIs and BIs as seen in our study. None-the–less, it is reassuring
that the results favoring early ART seem to be consistent across a
variety of clinical categories (Figure 4)
On the basis of these results, and although logistically challenging,
we recommend that ART be started early in the setting of acute
AIDS-related OIs if there are no major contraindications to doing so.
Waiting to complete OI treatment before initiating ART appears to
be associated with a higher risk of AIDS-related disease progression
and/or death without any significant benefit in terms of safety or
virological response. Initiation of ART in the setting of an acute
AIDS-related OI will require a multi-disciplinary team approach with
expertisein ART management tobe sure thatcareforthesecriticalill
patients is well-coordinated and effective. Although there are many
potential clinical challenges in initiating ART early in patients with
acute AIDS-related opportunistic infections the potential benefits to
such patients appears to be substantial.
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